Search results
Pfizer Inc. (NYSE:PFE) Position Increased by V Square Quantitative Management LLC
ETF DAILY NEWS· 6 days agoThe institutional investor owned 20,985 shares of the biopharmaceutical company’s stock after acquiring an additional 15,158 shares during the period. V Square Quantitative ...
Cartesian Therapeutics (NASDAQ:RNAC) Receives “Outperform” Rating from Oppenheimer
ETF DAILY NEWS· 7 days agoOppenheimer restated their outperform rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report issued on Friday, Benzinga reports. They currently have a $50.00 price ...
Gateway - Quartz
Quartz· 3 days agoNovo Nordisk and Johnson & Johnson both announced billion-dollar deals to acquire heart treatments. Walgreens Boots Alliance stock fell slightly in pre-market trading Thursday ...
Cantor Fitzgerald Reiterates “Overweight” Rating for Pfizer (NYSE:PFE)
ETF DAILY NEWS· 3 days agoPfizer (NYSE:PFE – Get Free Report)‘s stock had its “overweight” rating reissued by equities researchers at Cantor Fitzgerald in a report issued on Monday, Benzinga reports ...
Park National Corp OH Lowers Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 3 days agoThe institutional investor owned 446,577 shares of the biopharmaceutical company’s stock after selling 23,764 shares during the quarter. Park National Corp OH’s holdings in ...
Ables Iannone Moore & Associates Inc. Purchases New Stake in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 4 days agoAbles Iannone Moore & Associates Inc. bought a new stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) during the 4th quarter, according to the company in its most recent disclosure with ...
Pfizer Inc. (NYSE:PFE) Shares Sold by CoreFirst Bank & Trust
ETF DAILY NEWS· 4 days agoThe fund owned 42,156 shares of the biopharmaceutical company’s stock after selling 1,011 shares during the period. CoreFirst Bank & Trust’s holdings in Pfizer were worth ...
Kyverna's CAR-T relapse in lupus dents autoimmune hopes amid biotech gold rush
FierceBiotech· 5 days agoThe “remarkable” success of chimeric antigen receptor T-cell therapy (CAR-T) in lupus has led to a...
ReviR Therapeutics Reaches Milestone in Novel Splicing Therapy Development in Collaboration with...
Morningstar· 5 days agoReviR Therapeutics, a biotechnology company specializing in the development of small molecule RNA splicing modulators for neurogenetic diseases and oncology indications, and Asieris Pharmaceuticals ...
